Chris Lau

Chris Lau

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Delta Air Lines, Inc. Stock Is Undervalued by 55 Percent

Despite low valuations on the stock market that would attract value investors, Delta Air Lines, Inc. (NYSE:DAL) is stuck in a downtrend in 2018. Delta…

A Big Bet on Gene Therapy Is Just What Novartis AG (ADR) Stock Needs

Novartis put its excess cash to good use by broadening its business into the gene therapy market. Competition could prove tough for NVS stock, but Novartis is ready for the challenge ahead.

Why Advanced Micro Devices, Inc.’s New APU Chip Matters

Advanced Micro Devices stock trades as though it has no potential to take market share from Intel. But the market is wrong on this call. Advanced Micro cut the price of its powerful advanced processing unit named Ryzen, a significant move for AMD.

Exact Sciences Corporation Could Break Out Despite Steep Drop in Biotech

Exact Sciences is a rapidly growing biotech firm whose decline looks overdone. Seasonal strength in the second quarter could renew bullish sentiment in EXAS stock.

Micron Technology, Inc. Stock Won’t See $60 Highs Again for Awhile

Shortly after reporting incredibly strong quarterly results and issuing a great outlook, shares of Micron Technology Inc. (NASDAQ: MU) topped out at around $60 a…